A Bioequivalence Study of (Cytarabine: Daunorubicin) Liposome for Injection
Status:
Not yet recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the bioequivalence of (cytarabine: daunorubicin)
liposome for injection and Vyxeos in elderly acute myeloid leukemia (AML) subjects.